Kinfo
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc.

EBSNYSEHealthcare·US · USD
$7.24
+0.91 (+14.38%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap371.22M USD
Enterprise value773.06M USD
Trailing P/E8.59
Forward P/E6.05
PEG ratio0.01
Price / sales0.42
Price / book0.95
Profitability
Gross margin57.19%
Operating margin28.34%
Profit margin-22.96%
Return on assets6.93%
Return on equity-40.29%
Income (TTM)
Revenue770.20M USD
Gross profit388.50M USD
EBITDA262.30M USD
Net income-176.80M USD
Diluted EPS-$3.40
Rev. growth (YoY)66.30%
Balance sheet
Total cash139.70M USD
Total debt588.20M USD
Debt / equity172.29
Current ratio5.42
Book value / share$6.66
Cash flow (TTM)
Operating cash flow97.70M USD
Levered free cash flow40.00M USD
Shares & price
Shares outstanding51.30M
Float49.07M
Held by institutions90.60%
Beta2.34
50-day MA$6.13
200-day MA$8.60
52-week high$14.06
52-week low$4.36
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Recent payments
  • 2016-08-01$1.86
Earnings (EPS)
DateEst.ActualSurprise2026-08-050.110.60+445.45%2026-05-290.740.92+24.32%2026-04-30-0.250.21+184.00%2026-03-24-0.40-1.00−150.00%2026-02-260.11-0.43−490.91%
About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a life sciences company focused on preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats. Its current business centers on medical countermeasures and specialty products, including public health protection tools used by government agencies, healthcare providers, and other institutional customers. The company’s portfolio includes commercial products, medical countermeasure products, and services, with an emphasis on areas such as opioid overdose reversal, smallpox and anthrax preparedness, and contract development and manufacturing support. Emergent BioSolutions plays a specialized role in the healthcare and biodefense markets by supplying products and services designed to support emergency readiness and public health response across the United States and international markets.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
Employees
900
Headquarters
Gaithersburg, MD, United States

Frequently asked questions about Emergent BioSolutions Inc.